Analysts expect Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report $-0.32 EPS on March, 23.After having $-0.27 EPS previously, Miragen Therapeutics, Inc.’s analysts see 18.52% EPS growth. The stock increased 1.64% or $0.09 during the last trading session, reaching $5.57. About 102,005 shares traded. Miragen Therapeutics, Inc. (NASDAQ:MGEN) has 0.00% since February 24, 2017 and is . It has underperformed by 16.70% the S&P500.
STORNOWAY DIAMOND CORPORATION ORDINARY S (OTCMKTS:SWYDF) had an increase of 3.52% in short interest. SWYDF’s SI was 2.02M shares in February as released by FINRA. Its up 3.52% from 1.95M shares previously. With 5,700 avg volume, 354 days are for STORNOWAY DIAMOND CORPORATION ORDINARY S (OTCMKTS:SWYDF)’s short sellers to cover SWYDF’s short positions. The SI to STORNOWAY DIAMOND CORPORATION ORDINARY S’s float is 0.41%. It closed at $0.414 lastly. It is down 0.00% since February 24, 2017 and is . It has underperformed by 16.70% the S&P500.
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $160.90 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The company's clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.
Stornoway Diamond Corporation engages in the mining, acquisition, and exploration of diamond properties in Canada. The company has market cap of $333.02 million. The Company’s principal project is the Renard diamond project located in north-central Quebec. It has a 9 P/E ratio.